Advertisement
Australia markets open in 5 hours 44 minutes
  • ALL ORDS

    8,002.50
    +39.40 (+0.49%)
     
  • AUD/USD

    0.6637
    -0.0029 (-0.43%)
     
  • ASX 200

    7,749.70
    +34.20 (+0.44%)
     
  • OIL

    78.54
    +0.04 (+0.05%)
     
  • GOLD

    2,315.60
    -39.20 (-1.66%)
     
  • Bitcoin AUD

    100,780.70
    -3,374.41 (-3.24%)
     
  • CMC Crypto 200

    1,420.24
    +7.28 (+0.52%)
     

Tiziana Life Sciences Announces Purchase of Common Shares by Chairman and Acting CEO

Tiziana Life Sciences Ltd.
Tiziana Life Sciences Ltd.

NEW YORK, March 22, 2023 (GLOBE NEWSWIRE) -- Tiziana Life Sciences Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company enabling breakthrough immunotherapies via novel routes of drug delivery, today announces that it has been notified that Gabriele Cerrone, its Chairman and Acting Chief Executive Officer, purchased 8,000 common shares at $0.89 per share, bringing his total holding to 38,701,237 common shares.

About Foralumab
Activated T cells play an important role in the inflammatory process. Foralumab, the only fully human anti-CD3 monoclonal antibody (mAb), binds to the T cell receptor, dampens inflammation by modulating T cell function, thereby suppressing effector features in multiple immune cell subsets, an effect demonstrated in patients with COVID and with multiple sclerosis, as well as in healthy normal subjects. Intranasal foralumab Phase 2 trials are expected to start in Q3 2023 in patients with non-active SPMS. Immunomodulation by nasal anti-CD3 mAb represents a novel avenue for treatment of inflammatory human diseases.1

About Tiziana Life Sciences
Tiziana Life Sciences is a clinical-stage biopharmaceutical company developing breakthrough therapies using transformational drug delivery technologies to enable alternative routes of immunotherapy. Tiziana’s innovative nasal, oral and inhalation approaches in development have the potential to provide an improvement in efficacy as well as safety and tolerability compared to intravenous (IV) delivery. Tiziana’s lead candidate, intranasal foralumab, the only fully human anti-CD3 mAb, has demonstrated a favorable safety profile and clinical response in patients in studies to date. Tiziana’s technology for alternative routes of immunotherapy has been patented with several applications pending and is expected to allow for broad pipeline applications.

ADVERTISEMENT

For further inquiries:

Tiziana Life Sciences Ltd
Paul Spencer, Business Development and Investor Relations
+44 (0) 207 495 2379
info@tizianalifesciences.com

Investors:
Irina Koffler
LifeSci Advisors, LLC
646.970.4681
ikoffler@lifesciadvisors.com

 


1 https://www.pnas.org/doi/10.1073/pnas.2220272120